Pharmacological reduction of glucocorticoid activity can be achieved via several mechanisms of action, including neuromodulatory compounds which reduce corticotropin (ACTH) release from pituitary tumors, steroidogenesis inhibitors which reduce cortisol levels by adrenolytic activity and/or direct enzymatic inhibition, and finally glucocorticoid receptor (GR) antagonists which block cortisol action at its receptor [6, 7]. This evidence concerns the gene NR3C1 and pituitary tumor.